What's the deal with peptides? The hyped market under U.S. review
A U.S. Food and Drug Administration review panel began evaluating seven peptides for potential compounding amid rising popularity and concerns over their safety and efficacy. Medical experts, including orthopedic surgeon Alexander Weber, warn that insufficient clinical data exists to support the use of these substances, which include BPC-157 and TB-500. Despite restrictions, peptides are widely available online, raising concerns about the quality and safety of products from unregulated sources.